KMKatharina Mohr

Katharina Mohr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katharina Mohr has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of catheter-directed thrombolysis on the socio-economic burden of pulmonary embolism in Germany: a cost-effectiveness analysis

    by Katharina Mohr, Konstantinos C Christodoulou, Stefano Barco, Luca Valerio, Thomas Neusius, Karsten Keller, Lukas Hobohm, Markus Vosseler, Timo Uphaus, Marianne Hahn, et al.

    Aims: Catheter-directed treatment has yielded promising results in acute pulmonary embolism (PE), but state-of-the-art health economic evaluation of interventional treatment options is needed for healthcare systems to endorse its integration into clinical practice. We sought to provide an evidence-based comprehensive evaluation of the cost-effectiveness of catheter-directed thrombolysis (CDT) in PE. Methods and results: A systematic review and meta-analysis were conducted to retrieve outcomes of patients with intermediate- or high-risk PE treated with CDT vs. standard of care (SoC). A cost-effectiveness analysis model was developed, comparing CDT with SoC from the healthcare provider’s (payer’s) and the societal perspective in Germany (population of 84 million). A dynamic budget impact analysis (BIA) model was applied, assuming gradually increasing adoption of CDT. Over a 5-year time horizon, CDT resulted in 4.13 life-years (LY) and 3.58 quality-adjusted life years (QALY), compared with 3.90 LY and 3.38 QALY with SoC. From the payer’s perspective, the incremental cost-utility ratio (ICUR) for CDT was €27 349 per QALY. From the societal perspective, costs were lower for CDT than for SoC (€33 313 vs. €37 501). Cost-effectiveness of CDT was confirmed when focusing on patients with intermediate-risk PE; it also persisted when only randomized controlled trials were considered. Probabilistic analysis confirmed the robustness of the model. Budget impact analysis showed that, despite the higher upfront treatment costs of CDT in the acute phase, cost savings can be expected in the long term. Conclusion: In selected patients with acute PE, catheter-directed interventions may improve patient outcomes while remaining within the acceptable cost-effectiveness threshold.

  • Open Access

    Burden and long-term impact of pulmonary embolism on health-related quality of life: a matched cohort study

    by Luca Valerio, Thomas Grochtdreis, Anna C Mavromanoli, Ioannis T Farmakis, Christina Abele, Thomas Neusius, Katharina Mohr, Konstantinos C Christodoulou, Lukas Hobohm, Karsten Keller, et al.

    Aims: It has not been conclusively established whether and to what extent pulmonary embolism (PE) affects health-related quality of life (HrQoL). We aimed to assess the long-term independent association of PE with HrQoL to provide reference values for interventional studies and support quantification of the burden of PE in terms of quality- or disability-adjusted life years (QALYs and DALYs). Methods and results: A total of 1005 patients from a prospective multicenter study, followed 3 and 12 months after PE, were successfully matched to 3058 individuals from the general population of the same country based on age, sex, and key comorbidities. Differences between acute PE survivors and matched controls in the ordinal EQ-5D-5L HrQoL dimensions were assessed using multivariable ordinal regression, in the HrQoL index (reflecting overall HrQoL) using multivariable-adjusted mixed linear regression. Both multiple imputation and complete case analysis were performed. Compared with controls, patients reported worse HrQoL in the dimensions self-care, usual activities, and anxiety/depression, and worse HrQoL index at both 3 [adjusted difference −0.04 (95% CI: −0.06, −0.039) in a range from 0 to 1] and 12 months [−0.02 (95% CI: −0.04, −0.01)] in the imputation analysis. Complete case analysis showed similar results. The annual disability weight of PE for DALY calculation was conservatively estimated at 0.03 (95% CI: 0.02, 0.04). Conclusion: PE was independently associated with a moderate decrease in HrQoL, which persisted 12 months after the acute episode despite partial recovery over time. This degree of impairment is comparable to that imposed by several other cardiopulmonary diseases.


  • Open Access

    Socioeconomic Burden of Pulmonary Embolism in Europe: Shifting Priorities and Challenges for Novel Reperfusion Strategies

    by Katharina Mohr, Stefano Barco, Thomas Neusius, Stavros Konstantinides

    In-hospital case fatality related to acute pulmonary embolism (PE) has been falling since the beginning of this century. However, annual incidence rates continue to climb, and an increasing number of PE survivors need long-term follow-up, chronic anticoagulation treatment, and readmission(s) to the hospital. In European countries, median reimbursed hospital costs for acute PE are still moderate compared with the United States but can increase several-fold in patients with comorbidities and those necessitating potentially life-saving reperfusion treatment. The use of catheter-directed treatment (CDT) has constantly increased in the United States since the past decade, and it has now entered a rapid growth phase in Europe as well, estimated to reach an annual penetration rate of up to 31% among patients with intermediate–high- or high-risk PE by 2030. Ongoing randomised controlled trials are currently investigating the clinical efficacy and safety of these devices. In addition, they will deliver data permitting calculation of their cost-effectiveness in different health care reimbursement systems, by revealing the extent to which they can reduce complications and consequently the need for intensive care and the overall length of hospital stay. After discharge, key cost drivers are related to chronic cardiopulmonary diseases (other than PE itself) leading to frequent readmissions, persistent symptoms, and functional limitations which result in poor quality of life, productivity loss, and substantial indirect costs. Implementation of structured outpatient programmes with a holistic approach to post-PE care, targeting overall cardiovascular health and the patient's well-being, bears the potential to cost-effectively reduce the overall socioeconomic burden of PE.


  • Open Access

    Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study

    by Katharina Mohr, Philipp Mildenberger, Thomas Neusius, Konstantinos C Christodoulou, Ioannis T Farmakis, Klaus Kaier, Stefano Barco, Frederikus A Klok, Lukas Hobohm, Karsten Keller, et al.

    Aims: Patients surviving acute pulmonary embolism (PE) necessitate long-term treatment and follow-up. We estimated, the chronic economic impact of PE on the German healthcare system. Methods and results: We calculated the direct cost of illness during the first year after discharge for the index PE, analysing data from a multicentre prospective cohort study in Germany. Main and accompanying readmission diagnoses were used to calculate DRG-based hospital reimbursements; anticoagulation costs were estimated from the exact treatment duration and each drug's unique national identifier; and outpatient post-PE care costs from guidelines-recommended algorithms and national reimbursement catalogues. Of 1017 patients enrolled at 17 centres, 958 (94%) completed ≥3-month follow-up; of those, 24% were rehospitalized (0.34 [95% CI 0.30–0.39] readmissions per PE survivor). Age, coronary artery, pulmonary and kidney disease, diabetes, and (in the sensitivity analysis of 837 patients with complete 12-month follow-up) cancer, but not recurrent PE, were independent cost predictors by hurdle gamma regression accounting for zero readmissions. The estimated rehospitalization cost was €1138 (95% CI 896–1420) per patient. Anticoagulation duration was 329 (IQR 142–365) days, with estimated average per-patient costs of €1050 (median 972; IQR 458–1197); costs of scheduled ambulatory follow-up visits amounted to €181. Total estimated direct per-patient costs during the first year after PE ranged from €2369 (primary analysis) to €2542 (sensitivity analysis). Conclusion: By estimating per-patient costs and identifying cost drivers of post-PE care, our study may inform decisions concerning implementation and reimbursement of follow-up programmes aiming at improved cardiovascular prevention.


  • Open Access

    Drivers and recent trends of hospitalisation costs related to acute pulmonary embolism

    by Katharina Mohr, Lukas Hobohm, Klaus Kaier, Ioannis T. Farmakis, Luca Valerio, Stefano Barco, Christina Abele, Thomas Münzel, Thomas Neusius, Stavros Konstantinides, et al.

    Background and aims: The socio-economic burden imposed by acute pulmonary embolism (PE) on European healthcare systems is largely unknown. We sought to determine temporal trends and identify cost drivers of hospitalisation for PE in Germany. Methods and results: We analysed the totality of reimbursed hospitalisation costs in Germany (G-DRG system) in the years 2016–2020. Overall, 484 884 PE hospitalisations were coded in this period. Direct hospital costs amounted to a median of 3572 (IQR, 2804 to 5869) euros, resulting in average total reimbursements of 710 million euros annually. Age, PE severity, comorbidities and in-hospital (particularly bleeding) complications were identified by multivariable logistic regression as significant cost drivers. Use of catheter-directed therapy (CDT) constantly increased (annual change in the absolute proportion of hospitalisations with CDT + 0.40% [95% CI + 0.32% to + 0.47%]; P < 0.001), and it more than doubled in the group of patients with severe PE (28% of the entire population) over time. Although CDT use was overall associated with increased hospitalisation costs, this association was no longer present (adjusted OR 1.02 [0.80–1.31]) in patients with severe PE and shock; this was related, at least in part, to a reduction in the median length of hospital stay (for 14.0 to 8.0 days). Conclusions: We identified current and emerging cost drivers of hospitalisation for PE, focusing on severe disease and intermediate/high risk of an adverse early outcome. The present study may inform reimbursement decisions by policymakers and help to guide future health economic analysis of advanced treatment options for patients with PE. Graphical


  • Open Access

    Modelling costs of interventional pulmonary embolism treatment: implications of US trends for a European healthcare system

    by Katharina Mohr, Brent Keeling, Klaus Kaier, Thomas Neusius, Rachel P Rosovsky, John M Moriarty, Kenneth Rosenfield, Christina Abele, Ioannis T Farmakis, Karsten Keller, et al.

    Catheter-directed treatment (CDT) of acute pulmonary embolism (PE) is entering a growth phase in Europe following a steady increase in the United States (US) in the past decade, but the potential economic impact on European healthcare systems remains unknown. We built two statistical models for the monthly trend of proportion of CDT among patients with severe (intermediate- or high-risk) PE in the US. The conservative model was based on admission data from the National Inpatient Sample (NIS) 2016-2020, and the model reflecting increasing access to advanced treatment from the PERTTM national quality assurance database registry 2018-2021. By applying these models to the forecast of annual PE-related hospitalizations in Germany, we calculated the annual number of severe PE cases and the expected increase in CDT use for the period 2025-2030. The NIS-based model yielded a slow increase, reaching 3.1% (95% CI 3.0-3.2%) among all hospitalizations with PE in 2030; in the PERT-based model, increase would be steeper, reaching 8.7% (8.3-9.2%). Based on current reimbursement rates, we estimated an increase of annual costs for PE-related hospitalizations in Germany ranging from 15.3 to 49.8 million euros by 2030. This calculation does not account for potential cost savings, including those from reduced length of hospital stay. Our approach and results, which may be adapted to other European healthcare systems, provide a benchmark for healthcare costs expected to result from CDT. Data from ongoing trials on clinical benefits and cost savings are needed to determine cost-effectiveness and inform reimbursement decisions.